BeyondSpring Inc.

BYSI

KYG108301006

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 15:59:50 2024-07-05 EDT			5-day change	1st Jan Change
2.45 ^USD	-0.81%		+2.08%	+172.22%

07-01	BeyondSpring Inc.(NasdaqCM:BYSI) dropped from Russell Microcap Growth Index	CI
07-01	BeyondSpring Inc.(NasdaqCM:BYSI) dropped from Russell 3000E Growth Index	CI

BeyondSpring Inc.(NasdaqCM:BYSI) dropped from Russell Microcap Growth Index

July 30, 2024

Latest news about BeyondSpring Inc.

BeyondSpring Inc.(NasdaqCM:BYSI) dropped from Russell Microcap Growth Index	06-30	CI
BeyondSpring Inc.(NasdaqCM:BYSI) dropped from Russell 3000E Growth Index	06-30	CI
BeyondSpring Raises $3 Million via Stock Sale	06-12	MT
Top Premarket Decliners	05-21	MT
Transcript : BeyondSpring Inc. - Special Call	05-15
BeyondSpring Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-29	CI
North American Morning Briefing : Investors Brace -2-	04-29	DJ
North American Morning Briefing : Stock Futures -2-	04-22	DJ
North American Morning Briefing : Stock Futures -2-	04-15	DJ
BeyondSpring Says First Patient Dosed in Phase 2 Trial of Lung Cancer Combination Treatment	03-25	MT
Beyondspring Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide/Platinum in A Phase 2 Investigator-Initiated Study of First-Line Extensive-Stage Small-Cell Lung Cancer	03-25	CI
BeyondSpring Inc. Announces Executive Changes	03-18	CI
Top Premarket Decliners	03-06	MT
BeyondSpring Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	02-02	CI
BeyondSpring Receives Non-Compliance Notice From Nasdaq	01-10	MT
BeyondSpring Receives Notification From Nasdaq for Breaching Minimum Bid Price Requirements	12-19	MT
Transcript : BeyondSpring Inc. - Special Call	11-07
BeyondSpring Inc. Announces New Data That Translates Preclinical Proof-Of-Concept to Clinical Evidence of Plinabulin?s Immunomodulating Activity	11-07	CI
BeyondSpring Inc. Announces Retirement of Yanbin Xie as Board of Director	23-07-14	CI
North American Morning Briefing : Traders Bet Data -2-	23-07-12	DJ
North American Morning Briefing : China Data -2-	23-07-05	DJ
North American Morning Briefing : Chip Stocks Take -2-	23-06-28	DJ
BeyondSpring Inc.(NasdaqCM:BYSI) added to Russell Microcap Value Index	23-06-23	CI
BeyondSpring Inc.(NasdaqCM:BYSI) added to Russell 3000E Value Index	23-06-23	CI
North American Morning Briefing: Investors Eye Powell Testimony	23-06-21	DJ

BeyondSpring Inc. is a clinical-stage global biopharmaceutical company. The Company is focused on developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs. The Company operates through two segments: the Plinabulin pipeline and Targeted Protein Degradation (TPD) platform. Plinabulin is being developed as a pipeline in a drug in various cancer indications as a direct anti-cancer agent and to prevent chemotherapy-induced neutropenia (CIN). Plinabulin is a small molecule derived from a natural compound found in marine microorganisms. It is a selective immunomodulating microtubule-binding agent (SIMBA), which may provide multiple therapeutic opportunities. The TPD platform is utilizing molecular glue technology to develop therapeutic agents and discover and develop new chemical entities for the debilitating diseases and disorders. The Company is also developing three small-molecule immune agents.

Sector

Biotechnology & Medical Research

Calendar

2024-09-05 - Q2 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
BEYONDSPRING INC.	+172.22%	95.62M
VERTEX PHARMACEUTICALS INCORPORATED	+16.61%	122B
REGENERON PHARMACEUTICALS, INC.	+17.75%	112B
ARGENX SE	+18.69%	25.91B
BIONTECH SE	-24.11%	19.33B
GENMAB A/S	-18.05%	16.17B
BEIGENE, LTD.	-18.47%	15.6B
WUXI APPTEC CO., LTD.	-47.75%	14.65B
SAREPTA THERAPEUTICS, INC.	+57.35%	14.34B
NEUROCRINE BIOSCIENCES, INC.	+5.62%	14B

Bio Therapeutic Drugs